Total Funding
33
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
122345
Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.
- Mark J. Gergen: President, Chief Business Officer and Director
- Kristin Martin: Chief People and Administration OfficerPast Role: Poseida Therapeutics, Chief Human Resources Officer
About the Company
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of
hematological malignancies and solid tumors.
